Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

81. Variations in Testing for HIV and Other Sexually Transmitted Infections Across Gender Identity Among Transgender Youth. Full Text available with Trip Pro

Variations in Testing for HIV and Other Sexually Transmitted Infections Across Gender Identity Among Transgender Youth. Purpose: Transgender youth are at high risk for human immunodeficiency virus (HIV) and other sexually transmitted infections (STIs), but their rates of screening are unknown. This study sought to quantify HIV and other STI testing levels and to examine variations in testing levels across three categories of gender identity: transgender men, transgender women, and nonbinary (...) individuals. Methods: Between June 2017 and June 2018, 186 transgender youth aged 15-24 years were recruited into a randomized trial of home HIV testing supplemented with telehealth-based counseling. Information on sociodemographics, health care utilization, sexual activity, stress and resilience, and history of HIV and other STI testing was obtained. Multivariable logistic regression models were formulated to identify variations in testing for HIV and other STIs across gender identities. Results: Twenty

2019 Transgender health Controlled trial quality: uncertain

82. Methods to estimate the number of people living with undiagnosed HIV

. Available from: Accessed January 3, 2019. Hughson G. NAM: AIDSMAP. Factsheet: CD4 cell counts. 2017. Available from Accessed December 20, 2018. Hall HI, Song R, Szwarcwald CL, Green T. Brief report: Time from infection with the human immunodeficiency virus to diagnosis, United States. Journal of Acquired Immune Deficiency Syndromes. 2015;69(2):248–51. Song R, Hall HI, Green TA, Szwarcwald CL, Pantazis N. Using CD4 data to estimate HIV incidence, prevalence, and percent of undiagnosed infections (...) . Minimum size of the acquired immunodeficiency syndrome (AIDS) epidemic in the United States. The Lancet. 1986;328(8519):1320–2. U.S. Department of Health and Human Services. The stages of HIV infection. 2018. Available from: Accessed December 12, 2018. Wand H, Yan P, Wilson D, McDonald A, Middleton M, Kaldor J, et al. Increasing HIV transmission through male homosexual and heterosexual contact in Australia: Results from an extended back‐projection approach. HIV Medicine. 2010;11(6):395–403

2019 Ontario HIV Treatment Network

83. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

/EEA European Union/European Economic Area GP General practitioner HA-REACT Joint Action on HIV and Co-Infection Prevention and Harm Reduction HBV Hepatitis B virus HBsAg Hepatitis B surface antigen HCV Hepatitis C virus HIV Human immunodeficiency virus IC Indicator condition IFN Interferon INTEGRATE Joint Action on Integrating Prevention, Testing and Linkage to Care Strategies Across HIV, Viral Hepatitis, TB and STIs in Europe IUSTI International Union Against Sexually Transmitted Infections MSM (...) health guidance on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach 1 Executive summary Reaching and testing those at risk of infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) is still a public health challenge across Europe. One in two people currently living with HIV is diagnosed late in the course of their infection and an even larger proportion of the estimated 9 million Europeans living with chronic hepatitis B or C

2019 European Centre for Disease Prevention and Control - Public Health Guidance

84. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA

linkage to care for people newly diagnosed with HBV, HCV or HIV in primary care. 5 European AIDS Clinical Society. HIV guidelines version 9.0. Brussels: EACS, 2017. 6 European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153-94. 7 European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98. 8 European Centre for Disease (...) Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA Suggested citation: European Centre for Disease Prevention and Control. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Stockholm, December 2018 Reproduction is authorised, provided the source is acknowledged. PDF Print ISBN 978-92-9498-291-9 ISBN 978-92-9498-292-6 DOI 10.2900/809892 DOI 10.2900/579896 Catalogue number TQ-06-18-361-EN-N

2019 European Centre for Disease Prevention and Control - Public Health Guidance

85. Dolutegravir/rilpivirine (Juluca) for the treatment of human immunodeficiency virus type 1 (HIV-1)

Dolutegravir/rilpivirine (Juluca) for the treatment of human immunodeficiency virus type 1 (HIV-1) AWMSG SECRETARIAT ASSESSMENT REPORT Dolutegravir/rilpivirine (Juluca ® ) 50 mg/25 mg film-coated tablet Reference number: 2850 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics & Toxicology Centre (AWTTC). Please direct any queries to AWTTC: All Wales Therapeutics & Toxicology Centre (AWTTC) University Hospital Llandough Penlan Road Llandough Vale of Glamorgan CF64 2XX (...) /rilpivirine (Juluca ® ? ) 50 mg/25 mg film-coated tablet 1.0 KEY FACTS Assessment details Dolutegravir/rilpivirine (Juluca ® ? ) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA 50 copies/ml but lower than 200 copies/ml in the past 12 months 11 . Previous antiretroviral therapy regimens of two nucleoside reverse transcriptase inhibitors plus a third medicine (a non-nucleoside reverse transcriptase inhibitor, an integrase

2019 All Wales Medicines Strategy Group

86. Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review Full Text available with Trip Pro

Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review The Public Health Agency of Canada reviewed sexual transmission of HIV between serodiscordant partners to support examination of the criminal justice system response to HIV nondisclosure by the Department of Justice of Canada. We sought to determine HIV transmission risk when an HIV-positive partner takes antiretroviral therapy, has a suppressed (...) viral load or uses condoms.We conducted an overview and systematic review update by searching MEDLINE and other databases (Jan. 1, 2007, to Mar. 13, 2017; and Nov. 1, 2012, to Apr. 27, 2017, respectively). We considered reviews and studies about absolute risk of sexual transmission of HIV between serodiscordant partners to be eligible for inclusion. We used A Measurement Tool to Assess Systematic Reviews (AMSTAR) for review quality, Quality in Prognosis Studies (QUIPS) instrument for study risk

2019 EvidenceUpdates

87. Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial Full Text available with Trip Pro

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial In sub-Saharan Africa, individuals infected with HIV who are severely immunocompromised have high mortality (about 10%) shortly after starting antiretroviral therapy (ART). This group also has the greatest risk of morbidity and mortality associated with immune reconstitution inflammatory syndrome (IRIS), a paradoxical response to successful ART. Integrase inhibitors lead (...) to significantly more rapid declines in HIV viral load (VL) than all other ART classes. We hypothesised that intensifying standard triple-drug ART with the integrase inhibitor, raltegravir, would reduce HIV VL faster and hence reduce early mortality, although this strategy could also risk more IRIS events.In a 2×2×2 factorial open-label parallel-group trial, treatment-naive adults, adolescents, and children >5 years old infected with HIV, with cluster of differentiation 4 (CD4) <100 cells/mm3, from eight urban

2019 EvidenceUpdates

88. Medical and surgical abortion for women living with HIV. Full Text available with Trip Pro

Medical and surgical abortion for women living with HIV. The World Health Organization (WHO) guidelines for safe abortion recommend medical abortion with mifepristone and misoprostol or surgical abortion with vacuum aspiration or dilation and evacuation as safe and effective options for women. However, no specific clinical considerations are stipulated within these guidelines for women living with HIV. Concerns have been raised that women living with HIV may be at greater risk of adverse (...) abortion outcomes compared to HIV-uninfected women due to immunosuppression, high rates of co-infection with other sexually transmitted infections, and possible contraindications between medications used for medical abortion and antiretroviral therapy regimens.Our primary objective was to assess the effectiveness and safety of medical versus surgical abortion among women living with HIV. Our secondary objectives were to: (1) compare outcomes of medical and surgical abortion between women living

2018 Cochrane

89. HIV infection in pregnancy

and specialty care provided if the test is positive. All pregnant women with HIV should receive antiretroviral therapy (ART), as early as possible in the pregnancy, regardless of CD4 count or viral load. ART should be administered during the antepartum, intrapartum, and postnatal periods, as well as postnatally to the neonate. Breastfeeding is not recommended unless replacement feeding is not possible or feasible. Definition Human immunodeficiency virus (HIV) is a retrovirus that causes HIV infection (...) by infecting CD4 T cells and can lead to acquired immunodeficiency syndrome (AIDS). Van de Perre P, Simonon A, Msellati P, et al. Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. A prospective cohort study in Kigali, Rwanda. N Engl J Med. 1991 Aug 29;325(9):593-8. http://www.ncbi.nlm.nih.gov/pubmed/1812850?tool=bestpractice.com Pregnancy in women living with HIV is complicated not only by HIV infection itself but also by the medical and psychosocial comorbidities

2018 BMJ Best Practice

90. HIV self-testing at the workplace

to include HIVST. Workplaces must implement HIVST within the context of human rights principles as set forth in the ILO Recommendation concerning HIV and AIDS and the world of work, 2010 (Recommendation 200) 7 – which apply to any HIV testing. They include: Consent: HIV testing must be genuinely voluntary and free of any coercion. It is the workers’ choice to accept a test kit or not, after receiving information or offer of the test. Also, workers should be free to choose the place and time to test (...) a better price with the manufacturer due to larger procurement volumes. Resource considerations Adequate human and financial resources are essential to operationalize HIVST at the workplace. Resource needs will depend on the scale and nature of the programme and the models adopted for delivering HIVST. Human resource and infrastructure: Staffing needs should be considered: Will enough staff be available to cope with the likely increase in demand for HIV testing? In workplaces with on-site health-care

2018 World Health Organisation HIV Guidelines

91. Postpartum women living with HIV: Challenges related to retention in care, treatment adherence, and mental health

and Gynaecology Canada. 2014;36(8):721–34. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clinical Infectious Diseases. 2011;52(6):793–800. Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Internal Medicine. 2015;175(4):588–96. CATIE. Your guide to HIV (...) , McGregor DV, Sutton SH, Garcia PM, et al. Is maternal disclosure of HIV serostatus associated with a reduced risk of postpartum depression? American Journal of Obstetrics & Gynecology. 2016;215(4):521.e1–e5. Aaron E, Bonacquisti A, Geller PA, Polansky M. Perinatal depression and anxiety in women with and without human immunodeficiency virus infection. Women’s Health Issues. 2015;25(5):579–85. Stephens S, Ford E, Paudyal P, Smith H. Effectiveness of psychological interventions for postnatal depression

2018 Ontario HIV Treatment Network

92. British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium

British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium (2018) Suneeta Soni, Paddy Horner, Michael Rayment, Nicolas Pinto-Sander, Nadia Naous, Andy Parkhouse, Darren Bancroft, Carl Patterson, Helen Fifer 2 Introduction This is the first British Association of Sexual Health and HIV (BASHH) guideline (...) recommendations were presented at the joint British HIV Association and BASHH annual conference 2018. The draft guideline was appraised by the CEG using the AGREE instrument, posted on the BASHH website for a consultation period of 2 months, and piloted in a sample of clinics. In response to the consultation, suitable amendments were made to the guideline and the final draft was submitted to the CEG. The patient information leaflet (PIL) was reviewed by the CEG, BASHH patient and public panel, and also

2018 British Association for Sexual Health and HIV

93. Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) adults infected with human immunodeficiency virus-1 (HIV-1)

Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) adults infected with human immunodeficiency virus-1 (HIV-1) AWMSG SECRETARIAT ASSESSMENT REPORT Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy ® ) 50 mg/200 mg/25 mg film-coated tablets Reference number: 3414 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics & Toxicology Centre (AWTTC). Please direct any queries to AWTTC: All Wales Therapeutics & Toxicology Centre (AWTTC) University Hospital (...) from the date of the Final Appraisal Recommendation. AWMSG Secretariat Assessment Report Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy ® ? ) 50 mg/200 mg/25 mg film-coated tablets 1.0 KEY FACTS Assessment details Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy ® ? ) for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. ?This medicinal

2018 All Wales Medicines Strategy Group

94. HIV infection

HIV infection HIV infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  HIV infection Last reviewed: February 2019 Last updated: March 2019 Important updates 09 Nov 2018 US guidelines now recommend doravirine for the treatment of HIV Updated guidelines published by the US Department of Health and Human Services now recommend doravirine-based antiretroviral regimens as an initial option for the treatment of HIV (...) therapy (ART) as soon as possible. Pre-exposure prophylaxis with daily ART reduces the risk of HIV infection in adults who are at high risk for HIV acquisition and is recommended in select patients. Diagnosis and management varies between resource-intensive settings and resource-limited settings. Definition HIV infection is a pandemic infectious disease whose impact on societies is without precedent. It is caused by a retrovirus that infects and replicates in human lymphocytes and macrophages, eroding

2018 BMJ Best Practice

95. External quality assessment for HIV rapid tests: challenges and opportunities in Haiti Full Text available with Trip Pro

-efficient strategies are sought to ensure the quality of HIV diagnosis in LMICs. Qualified human resources, continuous training, supervision and community-tailored PT programmes remain key components for the success of HIV RDT quality management. (...) External quality assessment for HIV rapid tests: challenges and opportunities in Haiti HIV rapid diagnostic tests (RDTs) are instrumental in scaling-up HIV testing services (HTS) in low-income and middle-income countries (LMICs). HIV misdiagnosis is a growing concern in the era of expanded and decentralised access to HTS. External quality assurance (EQA) programme including proficiency testing (PT) for HIV RDTs is a priority to guarantee the accuracy and reliability of the patients' result

2018 BMJ global health

96. The pull of soccer and the push of Xhosa boys in an HIV and drug abuse intervention in the Western Cape, South Africa Full Text available with Trip Pro

The pull of soccer and the push of Xhosa boys in an HIV and drug abuse intervention in the Western Cape, South Africa There is growing interest in engaging men and boys in health and development programmes targeting the intersection of HIV risk, substance abuse, and violence. Understanding the conceptualisations of masculinities or masculine identities that shape both behaviours and opportunities for intervention is central to advancing the global agenda to engage men in health and development (...) interventions. This paper examines an intervention using soccer and job training to engage and deliver activities for HIV prevention, substance abuse, and gender-based violence in a South African township. A literature review provides theoretical, historical and social context for the intersection of gender, masculinity, soccer, violence, and sexual relationships. Qualitative data from in-depth interviews and focus groups is analysed using theoretical and contextual frames to elucidate the negotiation

2018 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

97. Antiretroviral resistance testing in HIV-positive people. Full Text available with Trip Pro

Antiretroviral resistance testing in HIV-positive people. Resistance to antiretroviral therapy (ART) among people living with human immunodeficiency virus (HIV) compromises treatment effectiveness, often leading to virological failure and mortality. Antiretroviral drug resistance tests may be used at the time of initiation of therapy, or when treatment failure occurs, to inform the choice of ART regimen. Resistance tests (genotypic or phenotypic) are widely used in high-income countries (...) , but not in resource-limited settings. This systematic review summarizes the relative merits of resistance testing in treatment-naive and treatment-exposed people living with HIV.To evaluate the effectiveness of antiretroviral resistance testing (genotypic or phenotypic) in reducing mortality and morbidity in HIV-positive people.We attempted to identify all relevant studies, regardless of language or publication status, through searches of electronic databases and conference proceedings up to 26 January 2018. We

2018 Cochrane

98. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferior (Abstract)

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferior Effective two-drug regimens could decrease long-term drug exposure and toxicity with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy and safety of a two-drug regimen compared with a three-drug regimen (...) for the treatment of HIV-1 infection in ART-naive adults.We conducted two identically designed, multicentre, double-blind, randomised, non-inferiority, phase 3 trials: GEMINI-1 and GEMINI-2. Both studies were done at 192 centres in 21 countries. We included participants (≥18 years) with HIV-1 infection and a screening HIV-1 RNA of 500 000 copies per mL or less, and who were naive to ART. We randomly assigned participants (1:1) to receive a once-daily two-drug regimen of dolutegravir (50 mg) plus lamivudine (300

2018 Lancet Controlled trial quality: predicted high

99. HIV-related opportunistic infections

HIV-related opportunistic infections HIV-related opportunistic infections - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  HIV-related opportunistic infections Last reviewed: February 2019 Last updated: November 2018 Summary The risk of HIV-related opportunistic infections (OIs) in HIV-infected people increases as the CD4+ count declines. Risk also increases in patients who are not receiving, or are not responding (...) to, antiretroviral treatment (ART). For most HIV-infected patients with an acute OI, ART should be considered within the first 2 weeks of initiation of treatment for the acute OI. However, in tuberculosis (TB) it might be appropriate to wait for a therapeutic response before ART is started. The use of ART among patients treated for OIs is complicated by drug interactions, drug toxicity profiles, and immune reconstitution inflammatory syndrome (IRIS). IRIS has been observed most commonly with mycobacterial

2018 BMJ Best Practice

100. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life

. • A negative serological test in children who have had a positive HIV RNA PCR test does not exclude ongoing HIV infection. • A detailed history of any possible previous ART given to the child and/or mother (or other likely source of infec- tion) should be documented. • The genotypic HIV resistance pro?le should be docu- mented at baseline. • The human leucocyte antigen (HLA) B*5701 genotype shouldbecon?rmednegativebeforeusingabacavir(ABC). • Clinical assessment should be carried out 3-4-monthly in children (...) infants at low risk of HIV transmission (maternal VL 100000 copies/ml); • in asymptomatic children aged 1–3 years irrespective of immune status and VL; • in sexually active adolescents, to minimize the risk of onward transmission; • in the presence of any signi?cant HIV-related clinical symptoms; • in hepatitis B virus (HBV) coinfection irrespective of immune status. 6. Which ART regimen to start as ?rst-line therapy • Children should start effective (at least three drugs) ART, usually a dual

2018 The Children's HIV Association